ANAVEX LIFE SCIENCES CORP.
Close on Oct 19, 2026
- Market cap
- $116.12B
- P/E (TTM)
- –
- Dividend yield
- –
About Anavex Life Sciences
Biological Products, (No Diagnostic Substances), SIC 2836
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company that develops therapeutics for central nervous system disorders. The company applies precision medicine and analyzes genomic data from clinical trials to identify biomarkers that guide treatment assessment. Its core research pipeline focuses on compounds that target sigma-1 receptor activation to restore cellular homeostasis. Key product candidates include ANAVEX 2-73, also known as blarcamesine, which is evaluated in oral capsule and liquid formulations, and ANAVEX 3-71. These therapies target conditions such as Alzheimer's disease, Parkinson's disease, and Rett syndrome.
The company operates its principal executive offices in New York, New York, and is incorporated in Nevada. Its clinical-stage research and development programs encompass clinical trials conducted across sites in North America, Europe, and Australia, including studies in Spain. Anavex has conducted trials across multiple patient age demographics and maintains ongoing evaluations of its pipeline candidates.
Summary of the business section of Anavex Life Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ANAVEX LIFE SCIENCES CORP.
- Headquarters
- New York, NY
- Address
- 630 5th Avenue, 20th Floor 10111
- Phone
- (844) 689-3939
- Website
- www.anavex.com
- Employees
- 34, Sep 30, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Fiscal year ends
- September 30
- Auditor
- GRANT THORNTON LLP, Melville, New York
Stock & identifiers
- Ticker
- AVXL
- Exchange
- Nasdaq
- IPO date
- Aug 2, 2006
- Shares outstanding
- 93M, Aug 28, 2026
- Public float
- $708.00M, Mar 31, 2025
- Filer category
- Large accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-4 reverse, Dec 29, 2015; 1-for-4 reverse, Oct 7, 2015
- SEC CIK
- 1314052
- CUSIP
- 032797300
- ISIN
- US0327973006
- LEI
- 549300K1I5L8COCQ8W36
- EIN
- 98-0608404
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christopher U. Missling | President and CEO, Director | 1,510,165 |
| Sandra Boenisch | PFO & Treasurer | 67,963 |
| Terrie Kellmeyer | Interim CEO | – |
| Axel Paeger | Director | – |
| Steffen Thomas | Director | 55,000 |
| Peter D.O. Donhauser | Director | 5,000 |
| Claus Vander Velden | Director | – |
| Jiong Ma | Director | – |
| Athanasios Skarpelos | Director | 1,306,458 |
Employees
Headcount reported in annual reports
“We currently have approximately thirty-four full-time employees, and we retain several independent contractors on a regular or as-needed basis.”
Corporate history
Events identified from SEC filings